机构：[a]Department of Neurosurgery, The Second Affiliated Hospital of Harbin Medical University, NanGang District, Harbin, Heilongjiang Province, 150001, China[b]Beijing Neurosurgical Institute, Capital Medical University, Dongcheng District, Beijing, 100050, China研究所北京市神经外科研究所首都医科大学附属天坛医院[c]Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Dongcheng District, Beijing, 100050, China重点科室诊疗科室神经外科神经外科首都医科大学附属天坛医院[d]Beijing Institute for Brain Disorders Brain Tumor Center, Dongcheng District, Beijing, 100050, China[e]China National Clinical Research Center for Neurological Diseases, Dongcheng District, Beijing, 100050, China[f]Chinese Glioma Cooperative Group (CGCG), Dongcheng District, Beijing, 100050, China[g]Department of Pathology, Sanbo Brain Hospital, Capital Medical University, Haidian District, Beijing, 100093, China
Recurrence and progression to higher grade lesions are key biological events and characteristic behaviors in the evolution process of glioma. Malignant astrocytic tumors such as glioblastoma (GBM) are the most lethal intracranial tumors. However, the clinical practicability and significance of molecular parameters for the diagnostic and prognostic prediction of astrocytic tumors is still limited. In this study, we detected ATRX, IDH1-R132H and Ki-67 by immunohistochemistry and observed the association of IDH1-R132H with ATRX and Ki-67 expression. There was a strong association between ATRX loss and IDH1-R132H (p < 0.0001). However, Ki-67 high expression restricted in the tumors with IDH1-R132H negative (p=0.0129). Patients with IDH1-R132H positive or ATRX loss astrocytic tumors had a longer progressivefree survival (p < 0.0001, p=0.0044, respectively). High Ki-67 expression was associated with shorter PFS in patients with astrocytic tumors (p=0.002). Then we characterized three prognostic subgroups of astrocytic tumors (referred to as A1, A2 and A3). The new model demonstrated a remarkable separation of the progression interval in the three molecular subgroups and the distribution of patients' age in the A1-A2-A3 model was also significant different. This model will aid predicting the overall survival and progressive time of astrocytic tumors' patients.
基金：
ACKNOWLEDGMENT We thank Yuling Yang for tissue sample collection and clinical data retrieval. This work was supported by grants from The Research Special Fund For Public Welfare Industry of Heath (No. 201402008), The National Key Research and Development Plan (No. 2016YFC0902500). National Key Technology Research and Development Program of the Ministry of Science and Technology of China (No. 2014BAI04B02), National High Technology Research and Development Program (No.2012AA02A508), Beijing Science and Technology Plan (No. Z131100006113018), International Science and Technology Cooperation Program (No. 2012DFA30470), National Natural Science Foundation of China (No.81372700, No. 81201993), Special Fund Project of Translational Medicine in the Chinese-Russian Medical Research Center (No. CR201417), Research Project of Chinese Society of Neurooncology, CACA (CSNO-2014-MSD08).
语种：
外文
PubmedID：
第一作者：
推荐引用方式(GB/T 7714)：
Cai J,Zhang C,Zhang W,et al.ATRX, IDH1-R132H and Ki-67 immunohistochemistry as a classification scheme for astrocytic tumors[J].Oncoscience.2016,3(7-8):258-265.doi:10.18632/oncoscience.317.
APA：
Cai, J,Zhang, C,Zhang, W,Wang, G,Yao, K...&Jiang, C.(2016).ATRX, IDH1-R132H and Ki-67 immunohistochemistry as a classification scheme for astrocytic tumors.Oncoscience,3,(7-8)
MLA：
Cai, J,et al."ATRX, IDH1-R132H and Ki-67 immunohistochemistry as a classification scheme for astrocytic tumors".Oncoscience 3..7-8(2016):258-265
